Recombinant human interferon (IFN) col (IFN-~I11) was compared with other human IFNs with regard to antigenic structure, using polyclonal and monoclonal antibodies. Antisera to recombinant IFN-cd or IFN-c~2c cross-neutralized the antiviral activity of other species of IFN-~, but not that of IFN-~ol. Antisera to IFN-/~ or IFN-? likewise had no effect on IFN<ol. Conversely, antiserum to IFN-~ol did not neutralize any of the other IFNs examined (IFN-el, -e2c, -~10, -c~B, -c~F, -fl, -?). None of four monoclonal antibodies to IFN-c~, including a broad-spectrum antibody that neutralized all five recombinant species of IFN-c~ tested, had any effect on the biological activity of IFN-~ol. Various immunoassays for IFN-e did not recognize IFN-ml. In immunoprecipitation experiments, radiolabeUed IFN-c~2c was not precipitated by antiserum to IFN-col. In contrast, antisera to human leukocyte IFN or 'lymphoblastoid' IFN did neutralize IFN-~ol, although with titres significantly lower than those towards the immunogen or recombinant species of IFN-c~. In conclusion, human IFN-~ol is antigenically different from human IFN-e, IFN-fl or IFN-?, but is a component of 'natural' mixtures of IFN species produced by virus-induced leukocytes or Burkitt's lymphoma cells.
INTRODUCTION
In mammals, class I interferon (IFN) genes form a superfamily consisting of two gene families, the alpha interferon (IFN-~) and the beta interferon (IFN-/~) genes, The number of genes in each family varies depending on the species. In cattle, at least 10 IFN<t genes and 10 IFN-/~ genes are found (Capon et al., 1985 ; Wilson et al., 1983) ; in horse, at least six IFN-ct genes and two IFN-/~ genes and in dog, at least six IFN-ct genes can be detected (Himmler et al., 1986 (Himmler et al., , 1987 . In humans, only a single IFN-/~ gene is present, whereas the IFN-ct family comprises more than 20 genes and pseudogenes (Henco et al., 1985) . Characteristically, all class I IFN genes are devoid of introns. The mature, secreted proteins corresponding to the human class I IFN genes consist of 166 (or, in one exception, 165) amino acids. The amino acid homology within the human (Hu) 1FN-ct family varies between 77~o and 100~o for each pair of proteins compared, whereas the homology with IFN-/~ amounts to only around 30~o.
Recently, a third class I IFN gene family was discovered independently by Capon et al. (1985) , Feinstein et al. (1985) , and Hauptmann & Swetly (1985) . In humans, this novel family consists of a single functional gene and at least three, probably four pseudogenes R. Hauptmann, unpublished data) . The mature protein corresponding to the intact gene (HuIFN-~ol) is 172 amino acids long; it shows only about 60~ sequence homology with human IFN-cts ( Fig. 1 ) and 26~o with IFN-/L On this basis, the newly discovered IFN family was provisionally designated IFN-omega (IFN-m) by Hauptmann & Swetly (1985) , but was considered a subfamily of IFN-~ by Capon et al. (1985) and termed IFN-~ subclass II (IFN-~tI) in contrast to the classical IFN-cts, IFN-ct subclass I (IFN-~g). As the Committee on the Nomenclature of Interferons has not yet recommended a final designation, this paper will refer 0000-7602 © 1987 SGM G.R. ADOLF to IFN-~ genes and IFN-o~I protein throughout. Human IFN-~ol like human IFN-fl contains a potential N-glycosylation site, whereas most species of the IFN-c~ family, and in particular all the major species represented in natural human leukocyte IFN (see below), lack this sequence. IFNc~s and IFN-o~I are coordinately induced in human peripheral blood leukocytes and lymphoid cell lines following viral induction (Capon et al., 1985; C. Pieler, unpublished data) . IFN-~o genes have been found not only in the human genome, but also in cattle, where this family comprises about 30 members (Capon et al., 1985) , as well as in horse (at least eight genes), but apparently have been deleted from the canine genome (Himmler et al., 1986 (Himmler et al., , 1987 . All IFN-o~ genes analysed to date are devoid of introns.
A distinction between human IFN-~ and IFN-fl was possible long before the availability of nucleotide and amino acid sequences, with the help of specific antisera; in fact, classification of IFNs was originally based on their antigenic properties (Stewart et al., 1980) . Human IFN, produced by induction of fibroblasts with synthetic, double-stranded RNA (poly I : C), contains only IFN-fl; antisera to this protein do not cross-react with IFN-~ in the classical neutralization assay which measures the inhibition by antiserum of the antiviral activity of an IFN preparation. Human leukocyte IFN, produced by induction of burly coat leukocytes with Sendal virus, contains many species of IFN-~ and trace amounts of IFN-fl; antisera to these preparations do cross-react with IFN-fl, but usually with titres well below 0.1 ~ of their activities towards the homologous preparation (Stewart, 1981) . Preliminary studies have shown that recombinant IFN-o~I is neutralized by antisera to leukocyte IFN, but not by antisera to IFN-fl (Capon et al., 1985) , indicating either that IFN-o~I is a constituent of leukocyte 1FN or that IFN-o~I cross-reacts with at least some of the IFN-c~ species present in leukocyte IFN, or both. I report here on a more detailed comparison of IFN<ol with other species of human IFNs, using a panel of antisera as well as monoclonal antibodies (MAbs).
METHODS

Interferons.
The following IFN preparations were used in this study. Recombinant HuIFN-~I and recombinant HuIFN-~2c (Escherichia coli-derived, purity > 95~) and recombinant 88 Gly, 111 Gly, (see Fig. 1 ), produced in yeast (unglycosylated), purity >95~] where all provided by G. Bodo of this Institute; recombinant HuIFN-~B and HuIFN-c~F (E. coil-derived, purity > 95 ~) were kindly provided by H. K. Hochkeppel, Ciba-Geigy, Basel, Switzerland; recombinant HuIFN-~10 (partially purified from E. coli lysates, sp. act. approx. 10 ~ units/mg), and 'natural' human leukocyte IFN (partially purified, sp. act, 1 x 106 to 2 x 106 units/mg) were kindly provided by K. Cantell, Helsinki, Finland; 'natural' HuIFN-fll (sp. act. > 10 s units/ml) was obtained from W, Merk, Thomae, Biberach, F.R.G. and recombinant purity > 99~) was produced by Genentech Inc., San Francisco, Ca., U.S.A.
Antisera. Antisera against highly purified, recombinant HuIFN-~2c, HulFN-cd, and HulFN<ol were prepared in this laboratory by immunization of BALB/c mice and/or New Zealand White rabbits. Sheep antisera against human leukocyte IFN and human IFN-fl as well as calf antiserum to human lymphoblastoid IFN were obtained from the Research Resources Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md., U.S.A. (catalogue numbers G-026-502-568, G-029-501-568 and G-030-501-553, respectively) . Rabbit antiserum to HulFN-~, was obtained from Genentech.
Monoclonal antibodies. Three of the four MAbs used have already been described (Adolf et al., 1982; Berthold et al., 1985) . The fourth antibody, EBI-10, was prepared similarly (G. R. Adolf, unpublished data). All antibodies are of the IgG isotype with ~,1 heavy chains as determined with the Bio-Rad mouse antibody sub-isotyping kit. They were produced in mice and purified to more than 90~ purity by 50~ ammonium sulphate precipitation followed by anion exchange chromatography or Protein A-Sepharose affinity chromatography.
Interferon bioassay. The antiviral activity of the IFN preparations was determined by a cytopathic effect inhibition assay using A549 human lung carcinoma cells (ATCC CCL 185) and mouse encephalomyocarditis virus. Briefly, cells grown in Eagle's minimal essential medium with 10~ foetal calf serum and antibiotics (penicillin, 100 units/ml, and streptomycin, 50 units/ml) were seeded into the wells of a microtitre plate (40000 cells/well in 100 BI medium containing 5 ~ foetal calf serum) and incubated for 6 h. Samples were then applied and diluted in serial twofold dilutions directly in the plates; two or more titrations were run in parallel for each sample. On each plate, four wells served as a cell control and four wells as virus control. A laboratory standard preparation of HulFN-cc2c was also titrated on each plate. The plates were incubated for 18 h, the medium was then removed and replaced by 50 vtl of a suspension of the challenge virus in medium with 5~ serum. The virus concentration was chosen so that about 95~ cytopathic effect was obtained after 24 h. At that time, the medium was removed, the cells were washed once with tap water, stained with 0.3 ~ methyl violet, washed and air dried. The absorbance Hauptmann & Swetly (1985) . of the stained cell layers was determined using an ELISA reader equipped with a 540 nm filter. The 50% endpoints of the dose-response curves were determined in relation to cell and virus controls on each of the plates. All samples were titrated in at least two, usually three, independent assays. All incubations were performed at 37 °C in a watersaturated atmosphere containing 5% COz. IFN titres are given in terms of the recombinant HulFN-~2 reference standard preparation, Gxa01-901-535. In the assay system described, 1 reference unit of this standard preparation corresponds to 1 to 2 antiviral units.
Neutralization assays. Neutralization assays were carried out essentially as recommended by the WHO Expert Committee on Biological Standardization (1984), Briefly, serial twofold dilutions of the antiserum (or of a solution of MAb) in medium with 5% serum were prepared in microtitre plates, mixed with an equal volume of the IFN solution containing 20 units/ml and incubated for 90 rain at 37 °C. Culture medium was removed from preseeded assay plates (see above) and replaced with the incubated IFN/antibody solution (100 ~tl/well). The plates were processed further as described above. Each plate contained IFN control wells for each of the IFNs tested as well as virus controls. The titre of the antibody preparation is the reciprocal of the dilution that reduces the antiviral G.R. ADOLF activity from 10 units/ml to 1 unit/ml (corresponding to a 50% reduction of the cytopathic effect). All antibody preparations were tested in at least two independent assays; two parallel titrations were run in each assay.
Radioimmune precipitation assay, Immunoprecipitation assays were performed largely as described by Chen et al. (1986) (corresponding to 1.6 ng protein) in 100 I.d phosphate-buffered saline (PBS) containing 0.l 9/00 gelatin, 0.05~ Tween 20, and 0.02~ sodium azide were added to 100 lal each of serial dilutions of rabbit antisera to HuIFN-c~2c or HuIFN-~o 1. The serum dilution medium consisted of PBS containing 2 ~ bovine serum albumin, 2 ~ rabbit serum and 0.02 ~ sodium azide. Negative controls received dilution medium only. The samples were incubated for 16 h at 4 °C, 100 l.tl of goat antiserum to rabbit immunoglobulin (Cappel Laboratories) diluted 1 : 5 in PBS was added and the samples were incubated for 3 h at room temperature. The precipitate was collected by centrifugation, dissolved in 200 p.1 0.25 M-NaOH and counted in a liquid scintillation counter.
Enzyme immunoassay. Enzyme-linked immunosorbent assays (ELISAs) were performed as described previously (Berthold et al., 1985) , except that sheep antiserum to human leukocyte IFN (kindly provided by K. Cantell) was used for coating the plates. Sheep immunoglobulins were partially purified by precipitation with 50~ ammonium sulphate and used at 10 ~tg/ml. Leukocyte IFN was employed as the reference standard. Briefly, microtitre plates were coated for 1 h and blocked with bovine serum albumin (5 mg/ml) for 1 h. Standard and samples were applied and diluted serially directly in the wells. Monoclonal antibody L3B7, conjugated with horseradish peroxidase, was added and the plates were incubated for 3 h, washed, and incubated for 30 min with a solution of orthophenylene diamine. The reaction was stopped with 2 M-sulphuric acid. The absorption at 492 nm (A492) of the reaction product formed was measured in an ELISA reader. All incubations were carried out at room temperature.
Immunoradiometric assay. A commercially available immunoradiometric assay, originally developed by Secher (1981) , was used according to the recommendations of the supplier (Celltech, Slough, U.K.).
RESULTS
By using standard neutralization assays, the antigenic relationship of a panel of HuIFNs to HuIFN-~ol was investigated. The results are summarized in Table 1 . An antiserum raised in mice against recombinant HuIFN-al neutralized the antiviral activity of other subtypes of IFNct, such as IFN-c~2c, -~10, -ceB, or ctF, although generally with a low neutralization titre (0.2 to 1.4~ of the titre towards the immunogen), but had no effect on IFN-ml. A rabbit antiserum against IFN-c~2c also cross-reacted (again with comparatively low titres) with all other IFN-~ species tested, but not with IFN-~ol ; mouse antiserum to IFN-a2c likewise did not affect the activity of IFN<ol. Conversely, rabbit antiserum to IFN<ol did not inhibit the biological activity of any of the IFN-a species. Antiserum to IFN<ol neutralized neither human IFN-fl nor IFN-y and vice versa; antisera to IFN-fl or IFN-y had no effect on IFN-ml. Antiserum to human leukocyte IFN reacted with all recombinant IFN-, species with a similarly high titre, and neutralized IFN-o01 with about 10~o of its activity towards the immunogen; this antiserum also showed a weak reaction with IFN-fl. Antiserum against human 'lymphoblastoid' IFN (derived from the B-lymphoid Burkitt's lymphoma cell line Namalwa) was also clearly active in neutralization of IFN-ml, again with about tenfold lower titre compared with IFN-c~2, one of the major components of Namalwa-derived IFN (Bodo & Adolf, 1983) .
To examine whether IFN-ml shares epitopes with IFN-a that are not related to its receptor binding site and would therefore not be detected by neutralization assays, immunoprecipitation experiments were performed. HuIFN-~2c, labelled with tritiated propionate, was incubated with serial dilutions of rabbit antisera against IFN-cc2c or IFN-ml, respectively; the rabbit antibodies were then precipitated with goat antiserum to rabbit immunoglobulin. Although both antisera showed similar neutralization titres towards the respective immunogen, anti-IFNml showed at least a 1000-fold lower precipitation titre than anti-IFN-c~2c (Fig. 2) .
Further studies on the antigenic relationship of IFN-col and IFN-~ used MAbs (Adolf et al., 1982; Berthold et al., 1985) . The reaction of these antibodies with several IFN-ct species in neutralization assays is shown in Table 2 . Three antibodies showed clearly distinct patterns of reactivity towards the different IFN-~ species tested, with neutralization assay endpoints varying by up to four orders of magnitude; in contrast, one antibody, L3B7, neutralized all five IFN-c¢ subtypes with similar affinity. None of these antibodies, however, was able to inactivate IFN-~ol.
To determine whether antibody L3B7, if not neutralizing, would at least bind to IFN-ml, a 3700  13  53  7  18  < 3  - §  --IFN-ct2c Rabbit  100  3300  32  14  13  <3  <3  <3  -IFN-ct2c Mouse  -8100  --<3  ---IFN-col Rabbit  <3  <3  <3  <3  <3  1600  <3  -<3  IFN- solid-phase sandwich enzyme immunoassay (ELISA) was developed, using sheep antiserum to leukocyte IFN for coating of the assay plates and L3B7, covalently bound to horseradish peroxidase, for detection of immobilized IFN. This assay was able to detect human leukocyte IFN at concentrations as low as 3 antiviral units/ml (Fig. 3) . As expected from the results of the neutralization assays, the ELISA also recognized all the recombinant IFN-a species tested with sensitivities varying between ~< 1 unit/ml (for IFN-ctl) and about 100 units/ml (for IFN-~10); in contrast, no significant signal was generated with IFN-c01 at concentrations as high as 106 units/ml (data not shown). Similar assays were carried out using MAb EBI-1 for coating and either L3B7 or EBI-10 conjugated to peroxidase; these assays showed sensitivities for IFN-~2c of 3 units/ml and 15 units/ml respectively, but gave negative results with IFN-ogl. Further, an immunoradiometric assay for IFN-ct (Secher, 1981) which uses polyclonal antiserum to leukocyte IFN for coating and a radiolabelled MAb, NK2, which binds the majority of IFN-~ species present in lymphoblastoid IFN (Allen et al., 1982) was also employed. This assay has a sensitivity of about 50 units/ml for leukocyte IFN, but was unable to detect IFN-o~I at concentrations up to 106 units/ml (data not shown). Finally, an immunoaffinity column consisting of EBI-1 antibody covalently coupled to Sepharose which can be successfully used for purification of IFN-ctl or IFN-ct2c by a method similar to that described by Allen et al. (1982) was unable to bind IFN-col from partially purified bacterial or yeast cell extracts (G. Bodo, unpublished data).
DISCUSSION
The various species of human IFN-~ are closely related in amino acid sequence, with homologies generally in the range of 80 to 85~. Antisera raised in rabbits or mice to recombinant IFN-~2c and IFN-~I, respectively, showed only slight cross-reactivity with other recombinant IFN-~ species, with neutralizing titres only about 1 ~ of the titre towards the immunogen; these results confirm and extend previous work by Exley et al. (1984) . It was therefore not unexpected that these antisera had no effect on the antiviral activity of IFN-col, which shares only about 60~ of its sequence with IFN-~I and -c~2c (Fig. i) . Moreover, immunoprecipitation experiments which should be able to identify antigenic relationships at epitopes not involved in receptor binding likewise failed to detect cross-reactivity between IFN~2c and IFN-o~I. Neutralization studies with MAbs to IFN-~, including one antibody that efficiently neutralizes all recombinant IFN-~ species tested, as well as various immunoassays that measure the binding of the MAbs to IFN-o)I, equally demonstrated lack of antigenic relationship. Although, from the experimental evidence presented, cross-reactivity of IFN-col with species of IFN-~ other than those examined here cannot be ruled out, this seems highly unlikely, particularly in view of the fact that none of the IFN-~s cloned and sequenced so far exhibits closer sequence homology to IFN-col than those species tested. We thus conclude that IFN-a~I is antigenically dissimilar to IFN-~. As expected on the basis of available sequence information, IFN-col is antigenically different also from IFN-/~ and IFN-y. Human class I IFN consequently comprises three antigenically distinct types of proteins, IFN-~, IFN-fl and IFN-~o.
In contrast to the results obtained with antisera to cloned species of IFN-~, neutralization of IFN-ogl antiviral activity was obtained when polyclonal antibodies to human leukocyte or 'lymphoblastoid' IFN were used. These results are most easily explained by assuming that IFNcol is a component of these natural mixtures of IFN species. The relative proportions of IFN-col and IFN-ct in these preparations cannot be determined from our results; if, however, similar immunogenicity of the various class I IFNs is assumed, IFN-col might well represent a major component: the neutralization titres against this protein are clearly lower (about 10-fold) than those against IFN-ct, but with antiserum to leukocyte IFN, are 100-fold higher than the titre against IFN-fl, known to occur as a trace component. This hypothesis gains support by reports that IFN-o~I clones can be identified in eDNA libraries derived from virus-induced leukocytes or Namalwa cells and that Northern analysis of mRNA from virus-induced leukocytes and lymphoma cells shows about equal levels of IFN-~ and IFN-~o mRNA (Capon et al., 1985; Hauptmann & Swetly, 1985; C. Pieler, unpublished data) .
Our results are of relevance to the nomenclature of this new type of human IFN. The IFN Nomenclature Committee comments that 'A new species designation [other than ~, fl, or ~; G.R.A.] would be required if there is a difference in more than about 50% of the encoded amino acid residues. This is a flexible criterion and other parameters (antigenic or biological) may be considered when deciding whether a new interferon belongs to an old species or not.'; further, 'It is generally possible to classify naturally occurring interferon proteins as ~, fl, or 7 species on the basis of their antigenic or biological properties. ' (Vil~ek et al., 1984) . Although sequence homologies between IFN-~ and IFN-col proteins are generally somewhat higher than 50 ~ (57 to 63~o in man, 57 to 60~ in horse, 53~o between bovine IFN-cd and bovine IFN-col; the additional six amino acids present at the C terminus of all IFN-co proteins identified so far have not been included in this calculation), the lack of antigenic cross-reactivity between human IFN-cts and IFN-col clearly supports the view that IFN-co, although related to IFN-ct more closely than to IFN-fl, represents a family of IFNs of its own, requiring a designation other than IFN-ct. Its designation as IFN-co thus seems justified; however, it should be emphasized that this designation is preliminary and the Nomenclature Committee might finally recommend a Greek letter other than co.
Further studies towards the characterization of the biological properties of human IFN-~ol and the isolation of natural IFN-~o are in progress.
